AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00766311 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Knee extension strength
Description: Maximum isometric knee extension strength will be measured with the subject seated in an adjustable straight-back chair. The pelvis will be fixed by an adjustable strap and the knee flexed to 45 degrees. The participant will exert a maximal voluntary force until their contraction is broken.
Study NCT00766311 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hand grip strength
Description: Hand grip strength in kilograms will be measured using a Jamar hand held dynamometer (Sammons Preston Rolyan, Nottinghamshire, UK). Participants will be seated with the shoulder at 0-10 degrees and the elbow in 90 degrees of flexion. The forearm will be positioned in neutral. Each participant will complete three trials, and the average used for analysis.
Study NCT00766311 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Flexibility
Description: Flexibility will be measured by having the participant perform the sit and reach test. A yardstick is placed on a firm flat surface and tape is placed across it at a right angle to the 15 inch mark. The participant sits with the yardstick between the legs with legs extended at right angles to the taped line on the floor. The heels of the feet touch the edge of the taped line and are 10-12 inches apart. The participant reaches forward with both hands as far as possible, keeping the hands parallel. The best value for three trials, in centimeters, at the most distant point of the fingertips is recorded.
Study NCT00766311 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ankle range of motion
Description: Ankle dorsiflexion active and passive range of motion will be measured with a goniometer. The goniometer is a reliable and valid measure of active and passive range of motion if the rater uses standard procedures
Study NCT00766311 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic capacity
Description: Participants will complete the modified Cooper test where they walk in a corridor as fast as possible for six minutes. The distance is recorded in meters and can also be used to estimate peak V02
Study NCT00766311 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Body composition and vital signs
Description: Height, body mass index, waist circumference, and blood pressure will be measured.
Study NCT02069717 — intervention group
Intervention type: OTHER
Intervention: Not applicable-observational study
Study NCT05492838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implantation with the Socket Shield Technique
Description: Immediate implant surgery applied with the Socket Shield Technique
Study NCT02198066 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dry Sterile Dressing
Description: Described in Arm Description.
Study NCT02198066 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metallic Silver Dressing
Description: Described in Arm Description.
Study NCT02198066 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ionic Silver Dressing
Description: Described in Arm Description.
Study NCT01748669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garlic oil
Description: Oral administration
Study NCT01748669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Garlic oil
Description: Oral administration
Study NCT04277416 — intervention group
Intervention type: DEVICE
Intervention: Total Hip Arthroplasty
Description: To evaluate Implant survival based on removal or intended removal of any component of the Entrada™ Hip System at five years of follow-up.
Study NCT02430012 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality improvement strategies
Description: Training with guidelines of secondary preventions; determining improvement goals; tools (workflow posters and cards, checklists to inform the use of secondary prevention medications); periodical quality feedback report.
Study NCT02164500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study NCT01921452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Qualitative POC TSH Kit
Description: A drop (approximately 30 mcL) of blood will be taken from subject's fingertip to test TSH qualitatively by using the qualitative POC TSH test kit according to the product specification on Day 1 to Day 5.
Study NCT01921452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Third generation TSH Kit
Description: One milliliter (mL) of subject's venous blood will be taken to test both qualitative and quantitative TSH levels, by using the third generation TSH test kit on Day 1 to Day 5.
Study NCT02522078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dry misoprostol
Description: 400 µg of dry misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
Study NCT02522078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: wet misoprostol
Description: 400 µg of wet misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
Study NCT02822157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Study NCT02822157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly
Description: physician's choice chemotherapy
Study NCT01525667 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 150M PLX-PAD
Description: Single course, multiple IM injections
Study NCT01525667 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 300M PLX-PAD
Description: Single course, multiple IM injections
Study NCT01525667 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single course, multiple IM injections
Study NCT03301233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol valerate and sildenafil
Description: (45 women will receive clomiphene citrate (clomid 50mg ®, Sanofi aventis) 2 tab. single dose orally from the 2nd day of the cycle for 5 days with oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
Study NCT03301233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate and sildenafil
Description: (45 women will receive clomiphene citrate (clomid 50mg ®, Sanofi aventis) 2 tab. single dose orally from the 2nd day of the cycle for 5 days with oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
Study NCT02435862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0mg Luminate®
Study NCT02435862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0mg Luminate®
Study NCT00635349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Aceclofenac 100 mg twice a day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and aceclofenac 100 mg twice a day from Day 29 to Day 85.
Study NCT00635349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol Hydrochloride Plus Acetaminophen
Description: Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam \[7.5 mg or 15 mg once daily\] or aceclofenac \[100 mg twice daily\]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
Study NCT02435862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.0mg Luminate®
Study NCT02435862 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Balanced Salt Solution for intravitreal injection in 0.10cc
Study NCT02565277 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccine
Study NCT02565277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01131845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UT-15C SR (treprostinil diethanolamine)
Description: Single dose, 1 mg UT-15C SR
Study NCT04252261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulforaphane
Description: To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
Study NCT04252261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placedo
Description: To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
Study NCT01112982 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: An Magnetic Resonance Imaging (with and without gadolinium contrast) of index joint will be performed (T1, T2, and STIR images).
Study NCT01112982 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Febuxostat
Description: All subjects in the sub-study will be started on febuxostat 40mg daily at baseline. If their serum urate level is > 6.0 at months 1 or 3, then the febuxostat dose will be increased to 80mg daily.
Study NCT01112982 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Colchicine
Description: Colchicine will be dosed at 0.6mg by mouth BID for the first three months then 0.6mg daily from months 3 to 6, and then discontinued at month 6.
Study NCT00633048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSA-789
Study NCT00633048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01395355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linking Individuals Being Emotionally Real (LIBER8)
Description: Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.
Study NCT01395355 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Management Control
Description: Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral techniques.
Study NCT00927758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
Description: fluticasone propionate/salmeterol diskus
Study NCT01482455 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Elevation of FFA during OGTT
Description: 0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1
Study NCT01482455 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elevation of FFA during OGTT
Description: 0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1
Study NCT01482455 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Elevation of FFA during Clamp
Description: 0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1.
Study NCT01482455 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elevation of FFA during Clamp
Description: 0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1.
Study NCT00409916 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioZ Dx
Study NCT00409916 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BioZ Dx
Study NCT01476761 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcutter XPRESS and Microcutter XCHANGE
Description: Surgical stapling devices
Study NCT00114218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT00114218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT02746770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Cawthorne and Cooksey exercises group
Description: Experimental: intervention group. Patients assigned to the experimental group will perform the Cawthorne and Cooksey exercises for vestibular rehabilitation in addition to their habitual treatment.
Study NCT02884128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP02
Description: PEP02 was administered on Day 1. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
Study NCT02884128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
Study NCT02884128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV
Description: 5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
Study NCT02319408 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative radiation
Description: Lobectomy for lung cancer following preoperative radiation
Study NCT01020032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual receptive music therapy by U sequence method
Description: During the hospitalization, the intervention group benefited from at least 2 daily sessions of music therapy between day 0 and day 10, and continued the musicotherapy at home until day 60.
Study NCT04595409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYB202 (Proposed ustekinumab biosimilar)
Description: Patients will receive 1 subcutaneous (SC) injection of FYB202 at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
Study NCT04595409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stelara® (Ustekinumab)
Description: Patients will receive 1 subcutaneous (SC) injection of Stelara® at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
Study NCT02645461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endocannabinoid palmitoylethanolamide (PEA)
Description: Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily
Study NCT02645461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Riluzole 50 mg twice daily
Study NCT02645461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riluzole
Description: Riluzole 50 mg twice daily
Study NCT00095719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: IM Solution, IM, Cohort 1 - 2.5mg (.33cc) maximum dose 5.0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 5.0mg (.67cc) maximum dose 10 mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 10 mg (1.3cc) or 5.0 mg (.67cc) maximum dose 15mg; 1 injection, 24 hour observation for all cohorts.
Study NCT00095719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM Solution, IM, Cohort 1 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 0mg; 1 injection, 24 hour observation for all cohorts.
Study NCT00968708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets
Study NCT00968708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Alogliptin placebo matching tablets
Study NCT02992418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
Description: 0.5 mL, intramuscularly at Day 0.
Study NCT01011179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teens Taking Charge
Description: The intervention is a 12-week multi-component treatment protocol that consists of self-management strategies (e.g., how to deal with stress and treatment related symptoms like pain), information (e.g., common problems associated with treatment and disease) and social support (e.g., monitored discussion boards and narratives in the form of written stories and video clips). It will be delivered on a restricted web-site and through regular contact with a trained coach by means of email and/or telephone using standardized scripts.
Study NCT01011179 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Management
Description: Adolescents' own best efforts at managing their JIA
Study NCT03048188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wound dressing
Description: Manuka honey wound dressing
Study NCT00288041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT01372774 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Undergo RT
Study NCT01372774 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: whole-brain radiation therapy
Description: Undergo radiotherapy (RT)
Study NCT02537119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic massage therapy
Description: Dynamic massage therapy on hamstring combined with knee extension
Study NCT00635349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride Plus Acetaminophen
Description: Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam \[7.5 mg or 15 mg once daily\] or aceclofenac \[100 mg twice daily\]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
Study NCT04325295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian drilling
Description: LOD will be done in the follicular phase.Follow up will be done on the next cycle by performing a TVUS examination at CD 13 and measuring the dominant follicles. Ovulation is considered if a follicle reached > 17 mm and is confirmed by measuring serum progesterone at CD 21.If ovulation is not achieved in the cycle following LOD, women will be prescribed Letrozole by the dose of 2.5 mg daily for 5 days starting from CD 3, and ovulation monitoring will be done similarly. If ovulation is not achieved, the dose is increased by 2.5 mg daily in the subsequent cycle until reaching the maximum dose of 7.5 mg daily for a total of 3 cycles.With persistent resistance to Letrozole in inducing ovulation, Gn will be prescribed for 3 cycles as in Gonadotrophin strategy
Study NCT04325295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant FSH (rFSH)
Description: A low-dose step-up protocol will be implemented. This starts on CD 3,The rFSH will be given through (IM) or(SC) injections with 75 IU and will be given once daily.Monitoring of the treatment will be done on CD 7 by TVUS and serum E2. Monitoring is individualized according to the response. Depending on the response and follicular growth, the dose may be adjusted by increasing 37.5 IU. If follicular growth failed, the dose is furtherly increased by the same amount until at least one follicle reaches 10 mm. The dose is maintained until at least one follicle reaches a diameter of 18 mm and no more than 2 follicles are bigger than 15 mm. Once reaching the desired diameter, the rFSH will be stopped and a trigger of ovulation by an IM injection of 5000 IU of hCG and sexual intercourse is encouraged on the day of trigger and the next day. Then serum P will be done 7 days after hCG injection to detect the occurrence of ovulation.
Study NCT02537119 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage therapy
Description: Rubbing on hamstrings
Study NCT02837328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Magnesium Supplement
Description: 400 mg Magnesium Citrate 1x daily for 12 weeks
Study NCT00690690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video (group-delivered video-based intervention)
Description: group-delivered video-based intervention
Study NCT00690690 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HCT
Description: Offer of HIV counseling and testing
Study NCT04461873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki by touching
Study NCT04461873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Reiki
Description: Sham reiki by gesturing and mimic imitation through touching
Study NCT03277001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban, po. 10mg/day（CrCl≥ 50 ml/min）or 5 mg /day (CrCl ≥ 30 and \< 50 ml/min) po.
Study NCT03277001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 40mg IH